A new class of antibiotics delivers promising trial results against tuberculosis

South Africa News News

A new class of antibiotics delivers promising trial results against tuberculosis
South Africa Latest News,South Africa Headlines
  • 📰 NatureMedicine
  • ⏱ Reading Time:
  • 21 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 12%
  • Publisher: 53%

A new class of antibiotics delivers promising trial results against tuberculosis. Read the latest in The Clinical Pipeline, from CyrilPedia

on 14 November 2022 the positive results of its open-label phase 2a trial of GSK30336656, a first-in-class drug for the treatment of tuberculosis. The molecule functions as an inhibitor of theenzyme leucyl-tRNA synthetase, blocking protein synthesis.

Patients with drug-susceptible pulmonary tuberculosis treated with the investigational drug for 14 days showed a significant, dose-dependent reduction in colony-forming units in their sputum, the trial’s primary endpoint. Andreas Diacon, GSK’s Chief Scientific Officer, stated in the press release that “GSK3036656 is a potential new antibiotic for tuberculosis that can be used in low, once-daily doses.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

NatureMedicine /  🏆 451. in US

South Africa Latest News, South Africa Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Proteomic signatures for identification of impaired glucose tolerance - Nature MedicineProteomic signatures for identification of impaired glucose tolerance - Nature MedicineA new study combines large-scale proteomics and machine-learning to identify proteins that can be used to identify individuals with impaired glucose tolerance, who would otherwise only be detectable with oral glucose tolerance tests MRC_Epid Julia_Czs
Read more »

Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer - Nature MedicineIntestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer - Nature MedicineIn a study of patients with advanced NSCLC undergoing anti-PD-1 therapy, the relative abundance of intestinal Akkermansia muciniphila associated with changes in the gut microbiome ecosystem and clinical outcomes GustaveRoussy LungCancer LCAM22
Read more »

Metabolomics - Nature BiotechnologyRecent patents relating to employing metabolomic data to diagnose disease states and determine the likelihood that a patient will respond to certain treatments.
Read more »

'Epic Adventures With Bertie Gregory' shows viewers behind the scenes of a nature docuseries'Epic Adventures With Bertie Gregory' shows viewers behind the scenes of a nature docuseriesEach episode allows the audience to feel like they are participating in the storytelling process, making the series more magical and more memorable.
Read more »

'Epic Adventures With Bertie Gregory' shows viewers behind the scenes of a nature docuseries'Epic Adventures With Bertie Gregory' shows viewers behind the scenes of a nature docuseriesEach episode allows the audience to feel like they are participating in the storytelling process, making the series more magical and more memorable.
Read more »

'Epic Adventures With Bertie Gregory' shows viewers behind the scenes of a nature docuseries'Epic Adventures With Bertie Gregory' shows viewers behind the scenes of a nature docuseriesEach episode allows the audience to feel like they are participating in the storytelling process, making the series more magical and more memorable.
Read more »



Render Time: 2025-03-01 01:16:57